Skip to content
drillr.ai
Sign up

02652.HK

CF PharmTech, Inc.

HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN

HKD 11.00
−6.78%
Ask drillr

  • Aug 31, 2026, 18:00 UTC

    Changfeng Pharmaceutical reported interim results for the six months ended June 2026, with revenue of RMB 210 million, up 2.1% year-on-year, gross profit of RMB 161 million, up 3.2%, and a net loss widening to RMB 10.51 million from RMB 1.23 million in the prior-year period, with no dividend declared.

    Source: